Kymera Therapeutics Inc (KYMR) — Capital Reinvestment Ratio
Latest as of December 2023:
1.44x
Kymera Therapeutics Inc (KYMR) has a Capital Reinvestment Ratio of 1.44x as of December 2023, meaning it reinvests 1% of its operating cash flow ($8.04 Million) in capital expenditures ($11.62 Million). See KYMR cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.44x
Capex / Operating Cash Flow
Operating Cash Flow
$8.04 Million
USD
Capital Expenditures
$11.62 Million
USD
Data as of
Dec 2023
Most recent filing
Kymera Therapeutics Inc Capital Reinvestment Ratio (2019–2020)
This chart tracks Kymera Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Kymera Therapeutics Inc (2019–2020)
Year-by-year Capital Reinvestment Ratio for Kymera Therapeutics Inc from 2019 to 2020. For live market cap and broader valuation context, see Kymera Therapeutics Inc (KYMR) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.10x | $88.13 Million | $9.10 Million | ▲ +247.4% |
| 2019 | 0.03x | $17.91 Million | $532.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow